QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer modelJessica Kalra, Marcel B. Bally|Breast Cancer Research|2009Cited by 73
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1Jessica Kalra, Marcel B. Bally|Oncogene|2010Cited by 49